Is Sat Kartar overvalued or undervalued?

As of 24 September 2025, the valuation grade for Sat Kartar has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 25.59, an EV to EBITDA of 15.92, and a ROCE of 48.39%.
In comparison to peers, Sat Kartar's valuation appears reasonable, especially when contrasted with Sun Pharma, which is deemed expensive with a PE ratio of 34.03, and Divi's Lab, classified as very expensive with a PE ratio of 68.78. Notably, Sat Kartar's PEG ratio stands at 0.00, suggesting potential growth opportunities that are not reflected in its current price. Recent stock performance shows a slight decline of 0.31% over the past week, outperforming the Sensex's drop of 1.08%, which may indicate resilience in a challenging market.